


LY3372689

Cat. No.:	HY-144681		
CAS No.:	2241514-56-5		
Molecular Formula:	C ₁₆ H ₂₂ FN ₅ O ₃ S		
Molecular Weight:	383.44		
Target:	Tau Protein		
Pathway:	Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (651.99 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.6080 mL	13.0399 mL	26.0797 mL
5 mM	0.5216 mL	2.6080 mL	5.2159 mL
10 mM	0.2608 mL	1.3040 mL	2.6080 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

LY3372689 (Formulaic Ia) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. LY3372689 can be used for tauopathies research, including Alzheimer's disease^{[1][2]}.

In Vivo

LY3372689 shows a dose-dependent change in OGA enzyme occupancy (EO) following a single oral dose with a maximum EO of greater than 90% in rat^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Nicolas Jacques Francois Dreyfus, et al. N-[4-fluoro-5-[(2s,4s)-2-methyl-4-[[5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor. Patent WO2018140299A1.

[2]. Sergey Shcherbinin, et al. Brain target occupancy of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme: Translation from rat to human. Alzheimer's & Dementia.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA